Highest-materiality recent filing
Labcorp Q2 revenue up 5.8% to $3.73B, adjusted EPS $4.99 beats; raises FY guidance
Q2 diluted EPS $3.64 vs $2.84 (+28.5%); adjusted EPS $4.99 vs $4.35 (+14.9%), beating prior guidance.
Labcorp Q1 revenue $3.54B (+5.8%), adjusted EPS $4.25 (+10.6%); raises FY guidance
Q1 diluted EPS $3.35 (+32.8% YoY); adjusted EPS $4.25 vs $3.84 consensus.
Labcorp enters $750M senior unsecured term loan due 2028
$750M term loan fully funded on March 20, 2026; matures March 20, 2028.
Labcorp Q4 revenue $3.52B (+5.6% YoY), adj EPS $4.07 beat; guides FY26 adj EPS $17.55-18.25
Q4 revenue $3.52B (up 5.6% YoY, organic 3.8%); diluted EPS $1.98; adjusted EPS $4.07 vs $3.45.
Labcorp EVP, President of Diagnostics Labs & COO Mark Schroeder to retire April 1, 2026
Mark Schroeder notified Labcorp of retirement effective April 1, 2026.
Labcorp Q3 adjusted EPS $4.18 vs $3.50; raises FY adjusted EPS midpoint to $16.15-$16.50
Revenue $3.56B (+8.6% YoY); diluted EPS $3.12 (vs $2.00); adjusted EPS $4.18 (vs $3.50).
Labcorp Q2 revenue $3.53B, Adj EPS $4.35; raises full-year guidance
Q2 revenue $3.53B (+9.5% YoY); diluted EPS $2.84 vs $2.43; adjusted EPS $4.35 vs $3.94.
Revenue $3.35B, GAAP diluted EPS $2.52 (down from $2.69), adjusted EPS $3.84 (up from $3.68).
Labcorp Q4 revenue $3.33B (+9.8% YoY); adj. EPS $3.45; FY2025 rev. midpoint ~$14.0B, adj. EPS $16.00
Q4 revenue $3.33B (+9.8% YoY); diluted EPS $1.70 vs ($1.95); adjusted EPS $3.45 vs $3.30; free cash flow $665.1M vs $412.4M.
Labcorp names Julia Wang CFO effective Dec 2; Glenn Eisenberg to retire April 2025
Julia Wang, former CFO of BeiGene, appointed EVP and CFO of Labcorp effective Dec 2, 2024.
Labcorp Q3 revenue $3.28B, adj EPS $3.50 vs $3.38; lowers FY adj EPS midpoint $0.10
Revenue $3.28B (+7.4% YoY); diluted EPS from cont ops $2.00 vs $2.11; adj EPS $3.50 vs $3.38.
Labcorp issues $2B in three tranches to refinance near-term debt maturities
Issued $650M 4.350% notes due 2030, $500M 4.550% notes due 2032, $850M 4.800% notes due 2034.
Labcorp subsidiary prices $2B senior notes offering to refinance existing debt
Labcorp subsidiary (LCAH) prices $2B in three senior note tranches: $650M at 4.350% due 2030, $500M at 4.550% due 2032, $850M at 4.800% due 2034.
Labcorp Q2 revenue $3.22B (+6.2%), adj EPS $3.94; raises revenue guidance, boosts buyback $1B
Q2 revenue $3.22B (+6.2% YoY); diluted EPS $2.43 vs $1.74; adjusted EPS $3.94 vs $3.42.
On November 19, 2024, Labcorp Holdings Inc. (“Labcorp”) announced that on November 15, 2024, Glenn Eisenberg notified Labcorp of his intention to retire from Labcorp effective April 30, 2025.
Julia Wang, age 54, was appointed to the position of Executive Vice President and Chief Financial Officer ("CFO").
As previously disclosed, on January 4, 2023, Paul Kirchgraber, Senior Advisor to the CEO, and former EVP and CEO of Labcorp’s Drug Development business segment, informed Laboratory Corporation of America Holdings (“Labcorp”) that he intended to depart Labcorp upon the completion of the spin-off of Fortrea Holdings Inc. in order to pursue other opportunities.
Laboratory Corporation of America Holdings (“Labcorp”) today announced that on June 5, 2023, Labcorp’s Board of Directors (the “Board”) appointed Paul B. Rothman as a member of the Board, effective June 6, 2023.
on May 4, 2023, Labcorp announced that Mark S. Schroeder, the current Executive Vice President, and President, Diagnostics Laboratory Operations and Global Supply Chain of Labcorp, a named executive officer, has been appointed to the position of Executive Vice President, President Diagnostics & Chief Operations Officer, effective May 1, 2023.
on May 4, 2023, Labcorp announced that Brian J. Caveney, the current Executive Vice President, President, Diagnostics and Chief Medical Officer of Labcorp, a named executive officer, has been appointed to the position of Executive Vice President, President Early Development & Chief Medical and Scientific Officer, effective May 1, 2023.
Mark S. Schroeder, the current Executive Vice President, and President, Diagnostics Laboratory Operations and Global Supply Chain of Labcorp, a named executive officer, has been appointed to the position of Executive Vice President, President Diagnostics & Chief Operations Officer, effective May 1, 2023.
Labcorp announced that Brian J. Caveney, the current Executive Vice President, President, Diagnostics and Chief Medical Officer of Labcorp, a named executive officer, has been appointed to the position of Executive Vice President, President Early Development & Chief Medical and Scientific Officer, effective May 1, 2023.
Thomas (Tom) Pike will join Labcorp as president and chief executive officer of its Drug Development Clinical Development business unit effective January 9, 2023
Paul Kirchgraber, EVP and CEO of Labcorp’s Drug Development business segment informed Labcorp that he intends to depart Labcorp upon the completion of the planned spin-off in order to pursue other opportunities.
Laboratory Corporation of America Holdings (“Labcorp”) today announced that on October 12, 2022, Labcorp’s Board of Directors (the “Board”) appointed Kirsten M. Kliphouse as a member of the Board, effective immediately.
Max materiality 0.90 · Median 0.30 · Most common event other